{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:02:14Z","timestamp":1771660934146,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"DFG","award":["TI 323\/4-1"],"award-info":[{"award-number":["TI 323\/4-1"]}]},{"name":"intramural funding"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jcv.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T12:40:51Z","timestamp":1548852051000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A pan-genotypic Hepatitis C Virus NS5A amplification method for reliable genotyping and resistance testing"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8736-0863","authenticated-orcid":false,"given":"Andreas","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Sophie","family":"Ennker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7799-3045","authenticated-orcid":false,"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2019.01.012_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCVC","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jcv.2019.01.012_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coph.2017.10.001","article-title":"Novel treatments for chronic hepatitis C: closing the remaining gaps","volume":"37","author":"Alkhouri","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0025","series-title":"Prescribing Information Vosevi","author":"US Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.jcv.2019.01.012_bib0030","series-title":"Prescribing Information Mavyret","author":"US Food and Drug Administration","year":"2017"},{"issue":"16","key":"10.1016\/j.jcv.2019.01.012_bib0035","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-017-0817-y","article-title":"Glecaprevir\/Pibrentasvir: first global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jcv.2019.01.012_bib0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2017.1351295","article-title":"Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C","volume":"11","author":"Voaklander","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jcv.2019.01.012_bib0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C Virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2019.01.012_bib0055","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.jcv.2019.01.012_bib0060","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 Hepatitis C Virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.jcv.2019.01.012_bib0065","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of Sofosbuvir and Velpatasvir, with and without ribavirin, in patients with HCV genotype 3 infection and cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2019.01.012_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0166-0934(94)90091-4","article-title":"Typing of Hepatitis C Virus isolates by DNA enzyme immunoassay","volume":"48","author":"Viazov","year":"1994","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2019.01.012_bib0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","article-title":"Post-treatment resistance analysis of Hepatitis C Virus from phase II and III clinical trials of Ledipasvir\/Sofosbuvir","volume":"66","author":"Wyles","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment of patients who failed 8 or 12 weeks of Ledipasvir\/Sofosbuvir- based regimens with Ledipasvir\/Sofosbuvir for 24 weeks","volume":"62","author":"Lawitz","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0085","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with Ledipasvir and Sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2019.01.012_bib0090","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 Hepatitis C Virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcv.2015.07.008","article-title":"Natural prevalence of resistance-associated variants in Hepatitis C Virus NS5A in genotype 3a-infected people who inject drugs in Germany","volume":"70","author":"Walker","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with Hepatitis C Virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0105","series-title":"Prescribing Information Zepatier","author":"US Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.jcv.2019.01.012_bib0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"EASL","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0115","series-title":"Recommendations for Testing, Managing, and Treating Hepatitis C","author":"AASLD","year":"2019"},{"issue":"2","key":"10.1016\/j.jcv.2019.01.012_bib0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"EASL","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0125","doi-asserted-by":"crossref","first-page":"e8209","DOI":"10.1371\/journal.pone.0008209","article-title":"Hepatitis C Virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice","volume":"4","author":"Chevaliez","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2019.01.012_bib0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153754","article-title":"Using NS5B sequencing for Hepatitis C Virus genotyping reveals discordances with commercial platforms","volume":"11","author":"Chueca","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2019.01.012_bib0135","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1128\/JCM.00586-13","article-title":"Sequencing assays for failed genotyping with the versant Hepatitis C Virus genotype assay (LiPA), version 2.0","volume":"51","author":"Larrat","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcv.2016.05.010","article-title":"New findings in HCV genotype distribution in selected West European, Russian and Israeli regions","volume":"81","author":"Kartashev","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2015.10.010","article-title":"Diagnosis of Hepatitis C Virus genotype 2k\/1b needs NS5B sequencing","volume":"41","author":"De Keukeleire","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.jcv.2019.01.012_bib0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcv.2017.04.008","article-title":"A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing","volume":"91","author":"Walker","year":"2017","journal-title":"J. Clin. Virol."},{"issue":"53","key":"10.1016\/j.jcv.2019.01.012_bib0155","article-title":"Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples","volume":"10","author":"Zhang","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.jcv.2019.01.012_bib0160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of Hepatitis C Virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2019.01.012_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV] \u2013 a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2019.01.012_bib0170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jmv.21631","article-title":"Hepatitis C Virus recombinants are rare even among intravenous drug users","volume":"82","author":"Viazov","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2019.01.012_bib0175","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos hepatitis C sequence database","volume":"21","author":"Kuiken","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcv.2019.01.012_bib0180","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1101\/gr.2.4.346","article-title":"PCR with degenerate primers containing deoxyinosine fails with Pfu DNA polymerase","volume":"2","author":"Knittel","year":"1993","journal-title":"PCR Methods Appl."},{"key":"10.1016\/j.jcv.2019.01.012_bib0185","doi-asserted-by":"crossref","first-page":"e0179562","DOI":"10.1371\/journal.pone.0179562","article-title":"An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains","volume":"12","author":"Andre-Garnier","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2019.01.012_bib0190","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cmi.2017.10.025","article-title":"Accurate Hepatitis C Virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection","volume":"24","author":"Knops","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2019.01.012_bib0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.meegid.2016.06.031","article-title":"Heterogeneous genomic locations within NS3, NS4A and NS4B identified for genotyping and subtyping of Hepatitis C Virus: a simple genome analysis approach","volume":"44","author":"Mansoor","year":"2016","journal-title":"Infect. Genet. Evol."},{"issue":"4","key":"10.1016\/j.jcv.2019.01.012_bib0200","article-title":"Genotypic resistance testing of HCV \u2013 is there a clinical need?","volume":"2016","author":"Walker","year":"2016","journal-title":"GMS Infect. Dis."},{"key":"10.1016\/j.jcv.2019.01.012_bib0205","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.02606-15","article-title":"Analysis of Hepatitis C Virus genotype 1b resistance variants in japanese patients treated with paritaprevir-ritonavir and ombitasvir","volume":"60","author":"Krishnan","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2019.01.012_bib0210","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2019.01.012_bib0215","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2019.01.012_bib0220","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and Sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"23","key":"10.1016\/j.jcv.2019.01.012_bib0225","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3851\/IMP3237","article-title":"Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals","author":"Palanisamy","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2019.01.012_bib0230","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12072-015-9624-2","article-title":"HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b","volume":"9","author":"Hirotsu","year":"2015","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.jcv.2019.01.012_bib0235","doi-asserted-by":"crossref","first-page":"W242","DOI":"10.1093\/nar\/gkw290","article-title":"Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees","volume":"44","author":"Letunic","year":"2016","journal-title":"Nucleic Acids Res."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219300241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219300241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T10:43:10Z","timestamp":1555324990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653219300241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":47,"alternative-id":["S1386653219300241"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2019.01.012","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pan-genotypic Hepatitis C Virus NS5A amplification method for reliable genotyping and resistance testing","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}